Published in Hepatitis Weekly, August 28th, 2000
Zarix announced that the FDA has indicated that the design of the pivotal Phase III trial for Thymitaq for the treatment of unresectable hepatocellular carcinoma is acceptable. This multi-center clinical study will be conducted as a global program with clinical study sites in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.